Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 26:4:226.
doi: 10.1186/1752-1947-4-226.

Anorectal stenosis after treatment with tumor necrosis factor alpha antibodies: a case series

Eoin Slattery  1 , Denise Keegan, Diarmuid O'Donoghue
Affiliations

Anorectal stenosis after treatment with tumor necrosis factor alpha antibodies: a case series

Eoin Slattery et al. J Med Case Rep. .

Abstract

Introduction: We identified three patients who developed anorectal stenosis after successful treatment with anti-tumor necrosis factor alpha (anti-TNF-alpha) agents.

Case presentation: Two patients, a 24-year-old Irish Caucasian man and a 64-year-old Irish Caucasian woman, developed symptoms attributable to anorectal stenosis four to six weeks after treatment. A further patient, a 25-year-old Irish Caucasian male, presented three years after treatment with anorectal stenosis, having been asymptomatic with his stenosis for the preceding three years. No patients had evidence of active inflammation at time of representation or had previous anal canal surgery.

Conclusion: Anorectal stenosis in these patients appears to be independent of active inflammation. No other cause of new stenosis could be identified. We postulate that rapid clinical response to anti-TNF-alpha agents led to aberrant mucosal healing. This in turn led to anorectal stenosis. This is the first report of this complication in association with the use of biologic agents.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Balloon dilatation of anorectal stenosis. This endoscopic picture shows the stenosis seen in patient 2. A balloon has been advanced through the stricture and has been inflated in the anorectal canal to dilate the patient's stenosis.
See this image and copyright information in PMC

References

    1. Physicians' Desk Reference. 59. Montvale, NJ: Medical Economics Co; 2005. pp. 1341–1359. Medical Economics Company, NJ, USA.
    1. Physicians' Desk Reference. 58. Montvale, NJ: Medical Economics Co; 2005. pp. 1145–1148. Medical Economics Company, NJ, USA.
    1. Van Dulleman HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tygat GN, Woody J. Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology. 1995;109:129–135. doi: 10.1016/0016-5085(95)90277-5. - DOI - PubMed
    1. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029–1035. doi: 10.1056/NEJM199710093371502. - DOI - PubMed
    1. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117(4):761–769. doi: 10.1016/S0016-5085(99)70332-X. - DOI - PubMed

LinkOut - more resources